drugset / Trial / NCT00891280
Dose-escalation Study of Oral CX-4945
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This Phase 1 study of oral CX-4945 is designed to test the safety, tolerability and highest safe dose level of this CK2 inhibitor in patients with advanced solid tumor cancers, Castleman's Disease or Multiple Myeloma.
Timeline
- Start
- 2009-02
- Primary completion
- 2011-12
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Silmitasertib | Small molecule | — | Oral |